12p12-13 deletion in prostate tumors and quantitative expression of CDKNIB and ETV6 candidate genes

Genes Chromosomes and Cancer

Volumn 31, Issue 2, 2001, Pages 199-200

  Latil, Alain ^a,b   Gurard, Marc ^b   Berthon, Philippe ^a   Cussenot, Olivier ^a,c  

^a CeRePP EA3104 and Urogne Gnopole ^*  (France)

^b Parc Scientifique de Luminy   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDKN1B; TRANSCRIPTION FACTOR ETV6; UNCLASSIFIED DRUG;

CANCER GRADING; CHROMOSOME 12P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE MAPPING; GENE TARGETING; HUMAN; HUMAN CELL; LETTER; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

CELL CYCLE PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 12; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0035002583     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.1135     Document Type: Letter

References (11)

1. Frequent deletion of chromosome 12p12-13 in children with acute lymphoblastic leukemia
2. Expression of p27Kip1 in prostatic adenocarcinoma
3. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma
4. The murine gene p27KIP1 is haplo-insufficient for tumour suppression
5. Identification of a 12p as a region of frequent deletion in advanced prostate cancer
6. Deletion mapping at 12p12-13 in metastatic prostate cancer
7. Loss of heterozygosiry at 12p12-13 in primary and metastatic prostate adenocarcinoma
8. The histology and prognosis of prostatic cancer
9. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
10. Diagnosis and staging of prostatic carcinoma
11. Low p27 expression predicts poor disease-free survival in patients with prostate cancer